Laboratorio Reig Jofre, S.A. · BME:RJF
Laboratorio Reig Jofre — 9M 2026 Earnings Presentation
16 slides from Laboratorio Reig Jofre's earnings presentation, November 2026
Slide 1: Financial results Third Quarter 2026 (9 months)
Financial results THIRD QUARTER 2026 (9 months)
Slide 2: Disclaimer
DISCLAIMER This presentation does not contain confidential material and may include publicly available market information that has not been independently verified by Reig Jofre. This information has been summarised and does not purport to be complete. The information contained in this presentation s
Slide 3: Key milestones for 9M26
KEY MILESTONES FOR 9M26 Results at the close of Q3 marked by: 6 months of disruption in Industrial plants Forté Pharma's supply chain in Spain in production ramp-up in France and Belgium Commercial New Biotech perimeter: operations in Europe continue Completion of Emintech IPCEI consolidation of Syn
Slide 4: Sales 9M26 by business unit vs 9M25
SALES 9M26 By business unit vs 9M25 SALES 9M26 € 241 M (0 %) Millions of euros 40% 39% 21% PHARMACEUTICAL SPECIALTY CONSUMER TECHNOLOGIES PHT PHARMACARE SPC HEALTHCARE CHC € 96 M / (2 % ) € 95 M / +10 % € 50 M / (12 %) Dermatology €27 M Antibiotics €35 M +1 % ENT RJ €10 M (1%) +0 % Osteoarticular €5
Slide 5: Sales 9M26 by business unit
SALES 9M26 By business unit SALES 9M26 € 241 M ((0 %) Millions of euros PHARMACEUTICAL 40% SPECIALTY 39% CONSUMER 21% TECHNOLOGIES PHT PHARMACARE SPC HEALTHCARE CHC Industrial recovery under way Progressing toward normalization after the fire Sustaining growth € 96 M / (2 % ) € 95 M / +10 % € 50 M /
Slide 6: International operations 9M26
INTERNATIONAL OPERATIONS 9M26 SALES 9M26 € 241 M (0 %) Sales by business type (€ M) Sales by region (€ M) EUROPEAN SUBSIDIARIES LICENSING & ADVANCED SERVICES Spain (B2C) DISTRIBUTION (B2B) CDMO €102 M €107 M OUTSIDE SPAIN € 148 M € 49 M € 43 M 42% 44% €134 M (4%) (0 % ) (6 % ) + 5% 56% of total 58%
Slide 7: Financial results 9M26: Profit and loss account
FINANCIAL RESULTS 9M26 Profit and loss account Millions of euros Revenue Gross Margin • Sales remained stable versus 9M25, affected by the fire at Forté Pharma (- 15% ) and offset by double- digit growth in the SPC business (+10% ). • The gross margin stands at 59% , - 1.5 points versus 9M25, due to
Slide 8: Financial results 9M26: EBITDA bridge
FINANCIAL RESULTS 9M26 EBITDA bridge Millions of euros We are growing the business and preparing for the future Extraordinary impacts EBITDA 9M26 PROFORMA 19 M€ +2 (4) 24 M€ (6) +3 +7% Part of the impact is (1) +1 19 M€ expected to be recovered before year-end 9M26: - 5M€ 9M25: + 1M€ EBITDA 9M25 Cre
Slide 9: Balance sheet – Assets and investments at 30 September
FINANCIAL RESULTS 9M26 Balance sheet – Assets and investments at 30 September Millions of euros ASSETS • Industrial investments focus on building Leanbio’s new € 77 M Investments 9M26 €28,5 M GMPplant, completing the adaptation of Barcelona’s Line 2 to the new regulation under GMP Annex 1, and commi
Slide 10: Balance sheet – Liabilities and debt at 30 September
FINANCIAL RESULTS 9M26 Balance sheet – Liabilities and debt at 30 September Millions of euros LIABILITIES Gross Financial Debt Net Financial Debt (NFD) FINANCIAL DEBT 2025 € 112 M € 137 M Credit institutions +38 NFD/EBITDA FINANCIAL DEBT Other financial liabilities - 12 4,8X IFRS 16 leases -1 €122 €
Slide 11: Evolution of the RJF share YTD Oct 26
EVOLUTION OF THE RJF SHARE YTD Oct 26 MARKET CAPITALIZATION € 214 M RJF (ISIN ES0165359029) 2.58€/Share - 30/10/2026 SHAREHOLDER COMPOSITION REIG JOFRE RJF YTD INVESTMENTS SL 6% 1% KAIZAHARRA + 1% 10% 6% CORPORACION 14% EMPRESARIAL SL ONCHENA, S.L. INVERSIONS L OLIVERA S.A. 63% Treasury shares SCRIP
Slide 12: Alternative performance measures
ALTERNATIVE PERFORMANCE MEASURES Management uses certain alternative performance measures in financial, operational and planning decision- making, as well as to evaluate the performance of the Group and its subsidiaries. Management considers that these alternative performance measures provide additi
Slide 13: Annex I: Income statement
ANNEX I Income statement Thousands of euros Sed ut perspiciatis INCOME STATEMENT (thousand euros) 30/09/2026 30/09/2025 V% Turnover 240.938 242.000 (0%) Cost of Sales (98.932) (95.627) 3% - Gross margin 142.007 146.373 (3%) - Work carried out for fixed assets 11.948 1.673 614% Other operating income
Slide 14: Annex II: Balance sheet
ANNEX II Balance sheet Thousands of euros Sed ut perspiciatis BALANCE SHEET (thousand euros) 30/09/2026 31/12/2025 Share capital 41.442 41.110 BALANCE SHEET (thousand euros) 30/09/2026 31/12/2025 Share Premium 19.000 19.000 Treasury shares (2.834) (2.836) Goodwill 26.470 26.495 Reserves 161.987 156.
Slide 15: Links and supplementary information
LINKS AND SUPPLEMENTARY INFORMATION FINANCIAL AND BUSINESS INFORMATION • Results publication | Laboratorio Reig Jofre CNMV COMMUNICATIONS • Other relevant information | Laboratorio Reig Jofre NEWSLETTER SUBSCRIPTION CENTER • Newsletter | Laboratorio Reig Jofre LATEST NEWS • News | Laboratorio Reig J
Slide 16: C/ Gran Capitán, 10 08970 Sant Joan Despí BARCELONA, SPAIN
C/ Gran Capitán, 10 08970 Sant Joan Despí BARCELONA, SPAIN T. +34 93 480 67 10 www.reigjofre.com www.reigjofre.com reigjofre.com
Laboratorio Reig Jofre — 9M 2026 Earnings Presentation on 6ix